NCT00585884 is a clinical trial in Breast Cancer, sponsored by University of California, Irvine.

Who is sponsoring NCT00585884?

NCT00585884 is sponsored by University of California, Irvine.

What condition does NCT00585884 study?

NCT00585884 studies Breast Cancer.

Is NCT00585884 still recruiting?

NCT00585884 is currently completed. Last updated 14 August 2023.

Last reviewed 2023-08-14 · How we verify

NCT00585884

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Following the Use of Gel Prosethetics in Breast Reconstruction

Completed Last updated 14 August 2023

What this trial tests

trial in Breast Cancer in 3 participants. Completed in 23 September 2013.

Timeline

1 February 2001

Primary endpoint
23 September 2013

23 September 2013

Quick facts

Lead sponsor	University of California, Irvine
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3
Start date	1 February 2001
Primary completion	23 September 2013
Estimated completion	23 September 2013
Sites	1 location across United States

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

University of California, Irvine

Who can join

Adults 18 to 80, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Following placement of silicone breast prosthetics for reconstruction

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other University of California, Irvine trials

Trials by the same sponsor.

NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction · NA · not yet recruiting
NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound · Phase 4 · not yet recruiting
NCT07527325 — Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma · Phase 2 · not yet recruiting
NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room · NA · not yet recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00585884 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
Last refreshed: 14 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00585884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing